PRIME SOURCE ENTERPRISES, INC

Gerald Chan is the principal and directs all investment activity for the office. Chan holds a PhD in biology and a master's in medical radiological physics from Harvard University, giving him the technical background to personally evaluate scientific opportunities. His approach is research-intensive and concentrated, rather than delegated to a large investment committee.

The office manages personal and family capital derived from the Hang Lung Group real estate fortune. Gerald Chan's father, Chan Tseng-hsi, founded Hang Lung Group and built its commercial property portfolio across Hong Kong and mainland China. Gerald Chan's brother, Ronnie Chan, leads the Hang Lung Group operating businesses, while Gerald focuses on investment and philanthropic activities through separate vehicles.

PRIME SOURCE ENTERPRISES, INC concentrates on early-stage therapeutics, platform biotech companies, and healthcare innovation, with a long-term, patient capital posture. Chan is known for making substantial bets on companies where his scientific background provides a diligence edge, often investing at the venture stage and holding through public listings. The portfolio spans direct investments, venture fund commitments, and occasional university spinout financings.

Morningside Group is the broader Chan family investment platform with a presence in Hong Kong, Shanghai, and other Asian markets, active across venture capital, private equity, and real assets. PRIME SOURCE ENTERPRISES, INC operates as Gerald Chan's personal investment vehicle, with a more concentrated focus on life sciences and biotechnology in the United States. The two entities share family ties but pursue distinct investment programs.

PRIME SOURCE ENTERPRISES, INC uses a hybrid model that includes direct equity investments in private and public biotech companies, limited-partner commitments to venture capital funds, and occasionally co-invests alongside academic institutions. The direct investing program is the most visible component, reflecting Chan's preference for concentrated positions in companies he has personally vetted.

The office is heavily concentrated in the United States, particularly the Boston-Cambridge biotechnology cluster, which aligns with Chan's academic and professional base in Massachusetts. It also selectively evaluates opportunities in Asia, leveraging the family's regional network. The firm does not publicly disclose a formal geographic allocation but the portfolio reflects this U.S.-centric, Boston-heavy orientation.

Yes. Chan is a major philanthropist, most notably through a $210 million gift to Harvard University in 2023 to support the Harvard T.H. Chan School of Public Health, named for his late father. His philanthropic giving often targets public health, education, and scientific research, operating through separate charitable entities distinct from the investment office's commercial activities.